Revolution Medicines, Inc. (FRA:42Z)

Market Cap	16.71B +112.9%
Revenue (ttm)	n/a
Net Income	-819.04M
EPS	-4.43
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	117
Open	87.00
Previous Close	83.50
Day's Range	86.50 - 88.50
52-Week Range	26.80 - 106.00
Beta	n/a
RSI	59.84
Earnings Date	Feb 25, 2026

About Revolution Medicines

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 809
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 42Z

Financial Performance

Financial numbers in USD